Immunological investigation in hepatic drug reactions

Clinical and Experimental Allergy, Supplement

Volumn 28, Issue 4, 1998, Pages 71-77

  Maria, V A J ^a   Victorino, R M M ^a  

^a INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; DRUG; ENALAPRIL; INDOMETACIN; PROSTAGLANDIN INHIBITOR;

ARTICLE; DIAGNOSTIC ACCURACY; HUMAN; IMMUNOLOGICAL PROCEDURES; IMMUNOPATHOGENESIS; LYMPHOCYTE PROLIFERATION; MAJOR HISTOCOMPATIBILITY COMPLEX; PRIORITY JOURNAL; STEM CELL; T LYMPHOCYTE; TOXIC HEPATITIS;

DRUG HYPERSENSITIVITY; HEPATITIS, TOXIC; HUMANS; LIVER; LYMPHOCYTE ACTIVATION; T-LYMPHOCYTES;

EID: 0031660620     PISSN: 09602178     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Sherlock S, Dooley J. Drugs and the liver. In: Sherlock S, Dooley J (eds ) Diseases of the liver and biliary system. Oxford. Blackwell Scientific Publications; 1993: 322-61.
2. Schenker S, Bay M. Drug disposition and hepatotoxicity in the elderly. J Clin Gastroenterol 1994; 18: 232-7.
3. Lee WM. Acute liver failure. N Engl J Med 1993; 329: 1862-72.
4. Zimmerman HJ, Maddrey WC. Toxic and drug-induced hepatitis. In: Schiff L, Schiff ER, eds Diseases of the liver. Philadelphia, JB Lippincott, 1993: 707-83.
5. Stricker BHC. Diagnosis and causality assessment of drug-induced hepatic injury. In: Dukes MNG (ed. ) Drug-induced hepatic injury. Amsterdam, Elsevier 1992: 1-13.
6. Farrell GC. Diagnosis of drug-induced liver diseases. In: Farrell GC (ed.) Drug induced liver disease. Edinburgh, Churchill Livingstone 1994: 153-62.
7. Kenna JG, Neuberger J, Williams R. Evidence for expression in human liver of halothane-induced neoantigens recognized by antibodies in sera from patients with halothane hepatitis. Hepatol 1988; 8: 1635-41.
8. Victorino RMM, Maria VAJ, Correia AP, de Moura MC. Floxacillin-induced cholestatic hepatitis with evidence of lymphocyte sensitization. Arch Intern Med 1987; 147: 987-9.
9. Maria VAJ, Silva JP, Victorino RMM. Agranulocytosis and liver damage associated to pyrazinobutazone with evidence for an immunological mechanism. J Rheumatol 1989; 16: 1484-5.
10. Maria VAJ, Victorino RMM. Hypersensitivity immune reaction as a mechanism of dilevalol associated hepatitis. Ann Pharmacother 1992; 26: 924-6.
11. Victorino RMM, Maria VAJ, Pinto L. Evidence for prostaglandin-producing suppressor cells in drug-induced hepatitis and implications in the diagnosis of drug sensitization. Clin Exp Immunol 1992; 87: 132-7.
12. Maria VA, Pinto L, Victorino RM. Lymphocyte reactivity to exvivo drug antigens in drug-induced hepatitis. J Hepatol 1994; 21: 151-8.
13. Maria VAJ, Victorino RMM. Lymphocyte proliferation to drugs: Analysis of the value of a 24 well lymphocyte culture system. Toxic In Vitro 1994; 8: 1041-4.
14. Gómez-Lechón MJ, Carrasquer J, Berenguer J, Castell JV. Evidence of antibodies to erythromycin in serum of a patient following an episode of acute drug-induced hepatitis. Clin Exp Allergy 1996; 26: 590-6.
15. Hofer T, Becker EW, Wiegand K, Berg PA. Demonstration of sensitized lymphocytes to trimethoprim-sulfamethoxazole and ofloxacin in a patient with cholestatic hepatitis. J Hepatol 1992; 15: 262-3.
16. Mackay IR. The immunological mediation of drug reactions affecting the liver. In: Farrell GC (ed. ) Drug-induced liver disease. Edinburgh, Churchill Livingstone 1994: 61-81.
17. Pessayre D. Role of reactive metabolites in drug-induced hepatitis. J Hepatol 1995; 23: 16-24.
18. van-Pelt FN, Straub P, Manns MP. Molecular basis of drug-induced immunological liver injury. Sem Liver Dis 1995; 15: 283-300.
19. Mauri-Hellweg D, Bettens F, Mauri D, Brander C, Hunziker T, Pichler WJ. Activation of drug-specific CD4+ and CD8+ T cells in individuals allergic to sulfonamides, phenytoin, and carbamazepine. J Immunol 1995; 155: 462-72.
20. Lecoeur S, Bonierbale E, Challine D et al. Specificity of in vitro covalent binding of tienilic acid metabolites to human liver microsomes in relationship to the type of hepatotoxicity: comparison with two directly hepatotoxic drugs. Chem Res Toxicol 1994; 7: 434-42.
21. Jenner AM, Timbrell JA, Influence of inducers and inhibitors of cytochrome P. 450 on the hepatotoxicity of hydrazine in vivo. Arch Toxicol 1994; 68: 349-57.
22. Berg PA, Becker EW. The lymphocyte transformation test: a debated method for the evaluation of drug allergic hepatic injury. J Hepatol 1995; 22: 115-8.
23. Zidar BL, Mendelow H, Winkelstein A, Shadduck RK. Diphenylhydantoin induced serum sickness with fibrin platelet thrombi in lymph node microvasculature. Am J Med 1975; 58: 704-8.
24. Rotmensch HH, Leiser A, Dan M et al. Evaluation of prajmalium-induced cholestasis by immunological tests. Arch Intern Med 1981; 141: 1797-801.
25. Goodwin JS, Messener RP, Bankhurst AD, Peake GT, Siki JH, Williams RC. Prostaglandin-producing suppressor cells in Hodgkin's disease. N Engl J Med 1977; 297: 963-8.
26. Victorino RMM. Indomethacin sensitive suppressor cells in Crohn's disease: a possible role in decreased lymphocyte responsiveness. J Clin Lab Immunol 1983; 11: 197-201.
27. Jakob T, Huspith BN, Latchman YE, Rycroft R, Brostoff J. Depressed lymphocyte transformation and the role of prostaglandins in atopic dermatitis. Clin Exp Immunol 1990; 79: 380-4.
28. Foley P, Kazazi F, Biti R, Sorrell TC, Cunningham ALHIV. infection of monocytes inhibits the T-lymphocyte proliferative response to recall antigen, via production of eicosanoids. Immunol 1992; 75: 391-7.
29. Maria VAJ, Victorino RMM. Diagnostic value of specific T cell reactivity to drugs in 95 cases of drug-induced liver injury. Gut 1997; 41: 534-40.
30. Salama A, Müller-Eckhardt C. The role of metabolite-specific antibodies in nomifensine-dependent immune hemolytic anemia. N Engl J Med 1985; 313: 469-74.
31. Berg PA, Brattig N, Diao GJ. Nachweis von Arzneimittelallergien mit hilfe das lymphozyten-transformationstests. Klinikarzt 1983; 12: 792-804.
32. Rodriguez RJ, Acosta D. Comparison of ketoconazole and fluconazole-induced hepatotoxicity in a primary culture system of rat hepatocytes. Toxicol 1995; 96: 83-92.
33. Moshage H, Yap SH. Primary cultures of human hepatocytes: A unique system for studies in toxicology, virology, parasitology and liver pathophysiology in man. J Hepatol 1992; 15: 404-13.
34. Bungy GA, Latchman Y, Rodda S, Geysen M, Roitt I, Brostoff JT. cell epitopes of major fraction of rye grass Lolium perenne (Lol p I) defined using overlapping peptides in vitro and in vivo. Clin Exp Immunol 1993; 94: 111-6.
35. Castello-Branco LRR, Griffin GE, Poulton TA, Dougan G, Lewis DJM. Characterization of the circulating T cell response after oral immunisation of human volunteers with cholera toxin B subunit. Vaccine 1994; 12: 65-72.
36. Beaune P, Dansette PM, Mansuy D et al. Human endoplasmic reticulum autoantibodies appearing in a drug-induced hepatitis are directed against a human liver cytochrome P-450 that hydroxilates the drug. Proc Natl Acad Sci USA 1987; 84: 551-5.
37. Kenna JG, Knight KM, van Pelt FNM. Immunity to halothane metabolite-modified proteins in halothane hepatitis. Ann N Y Acad Sci 1993; 685: 646-61.
38. Berson A, Freneaux E, Larrey D et al. Possible role of HLA in hepatotoxicity. An exploratory study in 71 patients with drug-induced idiosyncratic hepatitis. J Hepatol 1994; 20: 336-42.
39. Maria VAJ, Victorino RMM. Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis. Hepatol 1997; 26: 664-9.
40. Danan G, Bénichou C, Flahault A. Score d'imputation d'une atteinte hépatique aiguë à un médicament. Présentation d'une fiche d'évaluation. Gastroenterol Clin Biol 1993; 17: H22-4.